Post-ASH 2022 iwAL – ALL | VJHemOnc - 2 hours
Articles from: VJHemOnc
VJHemOnc is pleased to bring you a feature exploring the latest thinking on the application of MRD in AML trials and treatment, with leading...
-
📣 Check out our latest feature article exploring MRD as a clinical and regulatory endpoint in AML, with expert insights: 👉https://t.co/shx3gvfcGJ👈 #LeuSM #AMLsm #HemOnc - view on twitter
Mashup Score:2
VJHemOncPhase II trial of KER-050 in patients with myelofibrosis - 20 hours
Mashup Score:2
Claire Harrison, MD, FRCP, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, describes the mechanism of action...
-
🎥 Claire Harrison (@harrisoncn1) shares some insights into a Phase II trial assessing KER-050 in patients with myelofibrosis: 👉 https://t.co/wDvc368KKU 👈 #HemOnc #MPNsm #Myelofibrosis @ASH_hematology - view on twitter
Mashup Score:3
VJHemOncPost-ASH 2022 iwMDS | VJHemOnc - 24 hours
Mashup Score:3
Expert-led presentations & discussions on key abstracts in myelodysplastic syndromes (MDS) from ASH 2022 The Post-ASH 2022 iwMDS Virtual Workshop was held on 12...
-
🚨 If you want to find out the latest updates in MDS from ASH 2022, take a look at the on-demand content from our recent virtual workshop! All presentations & panel discussions can be found here: 👉https://t.co/JOaLCThjbh👈 #MDSsm #HemOnc #ImmunoOnc https://t.co/JOaLCThjbh👈 - view on twitter
Mashup Score:2
VJHemOncPhase II study of acalabrutinib plus RICE in R/R DLBCL - 1 day
Mashup Score:2
Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, reports on results from a Phase II trial (NCT03736616) assessing acalabrutinib...
-
#ASH22 | Great to catch up with @KrishPatelMD (@ProvSwedCancRes), who shared results from a Phase II trial assessing acalabrutinib plus RICE chemotherapy in R/R DLBCL. Watch here: https://t.co/ywSOqP7Wrv #HemOnc #DLBCL #LymSM @ASH_hematology - view on twitter
Mashup Score:5
VJHemOncAshutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM, University College London Hospitals NHS Foundation Trust, London, UK, comments on patient...
-
Find out more about the current challenges with selecting patients with AL amyloidosis for autologous transplantation in our interview with @awechalekar of @uclh: 🎥: https://t.co/MNxW6m0RK3 #ASH22 #Amyloidosis #BMTsm #HemOnc - view on twitter
Expert-led presentations & discussions on key abstracts in lymphoma and chronic lymphocytic leukemia (CLL) from ASH 2022 The Post-ASH 2022 Lymphoma & CLL Virtual...
-
🚨Missed out on our post-ASH 2022 lymphoma/CLL virtual workshop? Don't worry! We have everything you need on-demand here: ➡️https://t.co/zZAABtUyHP #LymSM #CLLsm #LeuSM #HemOnc #ImmunoOnc https://t.co/zZAABtUyHP - view on twitter
In this video, Eleni Gavriilaki, MD, PhD, G Papanikolaou Hospital, Thessaloniki, Greece, shares some updates on narsoplimab for the...
-
🎥 @elenicelli shares some recent updates on narsoplimab for the treatment of TA-TMA. Find out more in our exclusive interview from #ASH22: 👉https://t.co/bpHRWVKfjb👈 #HemOnc #ImmunoOnc - view on twitter
Mashup Score:3
VJHemOncJeremy Abramson, MD, Massachusetts General Hospital, Boston, MA, shares some insights into current immunotherapeutic agents being explored for the...
-
Jeremy Abramson (@MGHCancerCenter) shares some insights into the importance of CAR-T therapy & bispecifics in the treatment of #DLBCL: 👉https://t.co/4qP8X4EBos👈 #HemOnc #LymSM #WorldCancerDay #ImmunoOnc #CloseTheCareGap - view on twitter
Mashup Score:1
VJHemOncPost-ASH 2022 iwMPNs | VJHemOnc - 3 days
Mashup Score:1
Expert-led presentations & discussions on key abstracts in MPNs from ASH 2022 The Post-ASH 2022 iwMPNs Virtual Workshop took place on 17 January 2023,...
-
Our post-ASH 2022 iwMPNs virtual workshop took place recently, and you can now watch all expert-led presentations & panel discussions! 👉https://t.co/ifdRP6Bs9X👈 #MPNsm #HemOnc #ImmunoOnc https://t.co/ifdRP6Bs9X👈 - view on twitter
Expert-led presentations & discussions on key abstracts in ALL from ASH 2022 The Post-ASH 2022 iwAL Virtual Workshop was held on 11-12 January 2023,...
📣 Did you miss out on our recent Post-ASH 2022 iwAL Virtual Workshop, or want to view the content again? To watch ALL-focused presentations & discussions, visit: 👉https://t.co/6ab4UtFIaj👈 #ALLsm #LeuSM #HemOnc #ImmunoOnc https://t.co/6ab4UtFIaj👈 - view on twitter